ReviewFrontiers in pediatrics2020
Early Diagnosis and Intervention in Cystic Fibrosis: Imagining the Unimaginable.
Review in Frontiers in pediatrics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Review
- Respiratory Muscle Function in Children and Adolescents with Cystic Fibrosis in the Era of CFTR Modulator Therapies.Children (Basel, Switzerland) · 2025Article
- The ocular surface tear film as a biomarker for systemic health.The ocular surface · 2025Review
- Development of a 3D bioengineered human lung submucosal gland ductal airway model to study mucociliary clearanceCell biomaterials · 2025Article
- Impact of age at ivacaftor initiation on pulmonary outcomes among people with cystic fibrosis.Thorax · 2024Observational
- Diversity of CFTR variants across ancestries characterized using 454,727 UK biobank whole exome sequences.Genome medicine · 2024Article
- Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least OneAmerican journal of respiratory and critical care medicine · 2023Article
- The Relation between Vitamin D Level and Lung Clearance Index in Cystic Fibrosis-A Pilot Study.Children (Basel, Switzerland) · 2022Article
- Case report: Cystic fibrosis with kwashiorkor: A rare presentation in the era of universal newborn screening.Frontiers in pediatrics · 2022Article
- Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis-An Observational Pilot Study.Frontiers in pediatrics · 2022Article
- Unmasking Cystic Fibrosis in Adulthood, a Case Report.Journal of investigative medicine high impact case reportsArticle
- Efficacy of Adding Oral N acetyl Cysteine Supplement to the Cystic Fibrosis Treatment Regimen: A Randomized Quasi-Experimental Trial.Journal of research in pharmacy practiceArticle
- Risk Factors of Malnutrition in Children with Cystic Fibrosis: A 14-year Retrospective Study from Saudi Arabia.Saudi journal of medicine & medical sciencesArticle
- [Cystic Fibrosis in Latin America: Clinical Practices, Diagnosis, and Therapeutic Access: a Multicenter Cross-sectional Study].Acta gastroenterologica LatinoamericanaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cystic fibrosis is the most common life-shortening genetic disease affecting Caucasians, clinically manifested by fat malabsorption, poor growth and nutrition, and recurrent sinopulmonary infections. Newborn screening programs for cystic fibrosis are now implemented throughout the United States and in many nations worldwide. Early diagnosis and interventions have led to improved clinical outcomes for people with cystic fibrosis. Newer cystic fibrosis transmembrane conductance regulator potentiators and correctors with mutation-specific effects have increasingly been used in children, and these agents are revolutionizing care. Indeed, it is possible that highly effective modulator therapy used early in life could profoundly affect the trajectory of cystic fibrosis lung disease, and primary prevention may be achievable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.